H.I.G. Capital News
Zerigo Health Expands Board of Directors
Joseph E. Giles and Christina LaMontagne bring extensive operational and financial acumen and digital health expertise
SAN DIEGO – December 14, 2021 – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the appointments of Joseph E. Giles and Christina LaMontagne to the company’s Board of Directors. Both will serve as independent directors alongside Executive Chairman Glen Tullman, CEO John Schellhorn and investors Bruce Robertson and Paul LaViolette.
“Joseph and Christina both have deep roots in healthcare and bring extensive experience in growing and scaling companies,” said Schellhorn. “Zerigo Health is extremely fortunate to have them join our Board of Directors. Their insights and direction will be paramount as we continue expanding our services to members with chronic skin conditions and those who pay for their care.”
Most recently, Mr. Giles served as Founder and Chief Executive Officer of Midwest Vision Partners (MVP), one of the fastest-growing ophthalmology and optometry practices in the US. Prior to founding MVP, Mr. Giles served as Chief Operating Officer at Athletico Physical Therapy, the third largest physical therapy company in the US. He also brings extensive banking and investing experience, having worked for Vista Equity Partners, Barclays, Credit Suisse, and Goldman Sachs. Mr. Giles is a certified public accountant and licensed attorney, having earned a Bachelor of Business Administration, a Master of Business Administration and a Juris Doctor from the University of Michigan.
Ms. LaMontagne is the former Chief Operating Officer of leading women’s telehealth provider, Pill Club. She has been immersed in digital health for over a decade, leading digital corporate development at Johnson & Johnson, building health insurance tools at Nerdwallet, and serving as an investor and advisor to numerous pioneering digital health start-ups. Ms. LaMontagne earned a Bachelor’s Degree in Asian Studies from Dartmouth College and a Master of Business Administration from Harvard Business School. She was also a Fulbright Scholar in China.
“Zerigo Health’s innovative approach to treating various skin conditions has significantly advanced dermatological care and meaningfully improved patient outcomes and experiences,” said Giles. “I am excited to join the Zerigo Health Board and partner with the amazing leadership team they have assembled.”
“I’m thrilled to support Zerigo Health’s continued growth as a category-defining leader in delivering accessible chronic skin condition treatment,” said LaMontagne. “Zerigo is dramatically improving the patient experience, ultimately leading to significant improvements in outcomes and overall health for patients.”
Zerigo Health’s FDA-cleared, natural light therapy solution safely and effectively shifts dermatological care from the clinic to meet the health consumer wherever they are, at home, at work or wherever is convenient, keeping physicians and their patients with chronic skin conditions connected with personalized data and insights. Patients can easily self-administer clinically proven, American Academy of Dermatology guideline recommended narrowband ultraviolet B (NB-UVB) phototherapy using a handheld device and smartphone app. Prescription dosing is controlled via secure cloud-based technology, helping to ensure that patients treat safely in accordance with their physicians’ prescriptions. Patients are also remotely monitored and given personal coaching and support throughout their treatment journey.
“I look forward to partnering with Christina, Joseph, and the rest of our Board Members to help rapidly transform treatment options for consumers with chronic skin conditions,” said Tullman. “Zerigo Health is empowering people to better manage their chronic skin conditions from the comfort of home or any location they choose, while also helping to significantly reduce costs associated with legacy treatment methods and expensive therapeutics.”
In October 2021, Zerigo closed a $43 million Series B investment led by 7wireVentures and joined by General Catalyst, Dragoneer, Cigna Ventures, Leaps by Bayer and Leverage Health Solutions. The round also included participation by existing investors including SV Health Investors, H.I.G. Capital and Bluestem Capital. This new funding will allow the company to respond to the demand for new, cost effective and clinically proven solutions to treat chronic skin conditions.
Zerigo Health offers the only comprehensive home solution that seamlessly connects patients and providers to deliver optimal dermatological outcomes. Zerigo’s precision solution remotely treats and monitors patients with chronic skin conditions using narrowband ultraviolet B (NB-UVB) phototherapy, a proven, standard-of-care treatment. Patients benefit from the unique combination of advanced technology with personal coaching and support throughout their treatment journey, which results in documented increases in treatment adherence and patient satisfaction. To learn more, visit www.zerigohealth.com or on LinkedIn or Twitter.